Another Twist in Myocet Plot With $55 Million Zoticon-Led Financing for Sopherion
This article was originally published in Start Up
Executive Summary
Zoticon has licensed the liposomal formulation of doxorubicin (Myocet) from Sopherion Therapeutics, essentially rescuing the company on the edge of collapse and creating a new vehicle for Myocet's development.